Pfizer: COVID Vaccine Update Induces Immune Response in Mice

Pfizer announced today, Wednesday, that its modified vaccine developed in collaboration with BioNTech for the prevention of COVID-19 is expected to be used this fall. The vaccine triggered a strong immune response by producing antibodies against the highly mutated coronavirus subvariant (BA.2.86) in a study conducted on mice prior to clinical trials. The Centers for Disease Control and Prevention had previously indicated that the (BA.2.86) variant may be more capable of infecting individuals who have previously contracted COVID or who have received prior vaccine doses. Moderna reported that clinical trial data on humans showed its updated vaccine is likely to be effective against the same variant.